Replace animal-derived antivenom with broadly-neutralizing recombinant human antibody cocktails

The proposal

Manufacture antivenom as a defined cocktail of recombinant human (or humanized) monoclonal antibodies selected to bind conserved, medically dominant toxin families, rather than as whole polyclonal serum raised by immunizing horses or sheep with whole venom. The goal is a small number of broad-spectrum products (ideally split only by the neurotoxic-elapid vs. hemotoxic-viper divide) instead of the dozens of narrow regional sera in use today.

Why it would work

Across medically important snakes, most lethality is driven by a handful of toxin families — three-finger toxins (3FTx), phospholipases A2 (PLA2), snake-venom metalloproteinases (SVMP), and serine proteases (SVSP). Because antibodies bind conserved structural epitopes shared across a family, one broadly-neutralizing antibody can cross-neutralize the same toxin class across many species. Targeting the shared core collapses the number of products required from hundreds toward single digits. Recombinant human antibodies also avoid the serum-sickness and anaphylaxis risks of heterologous animal IgG, and offer batch-to-batch consistency that whole-serum production lacks.

Evidence

In a 2025 Cell study, Glanville and colleagues (Centivax, Columbia University, NIAID) isolated two broadly-neutralizing human antibodies — one against long-chain and one against short-chain neurotoxins — from a hyper-immunized human donor, and combined them with the small-molecule PLA2 inhibitor varespladib. In mouse models the three-component cocktail gave full protection against 13 of 19 elapid species and partial protection against the remaining 6. Recombinant/oligoclonal antivenom design has also been advanced by the Laustsen group (Technical University of Denmark) and others.

Implementation path

Isolate and engineer broadly-neutralizing antibodies against each dominant toxin family; validate cross-species neutralization preclinically; combine into minimal cocktails; run first-in-human safety and then region-agnostic efficacy trials (the varespladib BRAVO design offers a species-agnostic trial template). Manufacturing would sit with biopharma partners rather than serum institutes.

Trade-offs and limitations

The 2025 result covers only elapid neurotoxins — it does not neutralize viper (hemotoxic/cytotoxic) venoms, which act by different mechanisms; a parallel antibody set is needed for SVMP/SVSP. Recombinant monoclonal manufacturing is currently far more expensive per dose than horse serum, so without volume and subsidy the affordability problem is not automatically solved. All current results are preclinical.